[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-nisotirostide-ly3457263-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":1264,"_id":1265,"_source":1266,"_file":1267,"_stem":1268,"_extension":1269},"\u002Fblog\u002Fzh\u002Fnisotirostide-ly3457263","zh",false,"","Nisotirostide（LY3457263）：一款只以「叠加」形式存在的 PYY 药物，以及数据真正说了什么","这里讲的是通识科普，不是医疗建议，也不是叫你去弄或者去用任何东西。Nisotirostide 是在研药物，全球任何地方都未获批准，既不能合法购买，也开不出处方。剂量我们一个字都不给——因为压根就没有公开的剂量，原因下文会说。文中的数字来自不同试验，人群和时长都不一样，不是头对头比较。","研究","tabler:flask-2","#2E9E8F","2026-08-05","2026年8月","12 min","myPeptides Team","\u002Fassets\u002Fnisotirostide_hero.png",{"type":19,"children":20,"toc":1251},"root",[21,28,48,53,60,79,117,135,147,152,157,326,345,350,355,361,370,397,414,419,431,437,442,454,466,478,483,555,560,579,591,596,602,613,644,654,754,766,771,776,999,1004,1010,1015,1020,1025,1045,1050,1062,1067,1072,1101,1106,1111,1116],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31,33,39,41,46],{"type":27,"value":32},"最近几个月论坛上冒出一个新名字，说法几乎千篇一律：",{"type":22,"tag":34,"props":35,"children":36},"strong",{},[37],{"type":27,"value":38},"Nisotirostide",{"type":27,"value":40},"，「加在替尔泊肽或司美格鲁肽上面的那个东西」。它的代号是 ",{"type":22,"tag":34,"props":42,"children":43},{},[44],{"type":27,"value":45},"LY3457263",{"type":27,"value":47},"，公司是礼来。和绝大多数灰市新词不同，这套说法里有一部分是真的：这个分子确实就是按「加在别人上面」设计的。没有任何一项试验让它在肥胖人群里单独对照安慰剂——组合不是生物黑客的自行发挥，而是试验方案本身。",{"type":22,"tag":23,"props":49,"children":50},{},[51],{"type":27,"value":52},"只是同一轮查证还翻出了第二个发现，很不好听，而它在这篇文章里的分量和第一个一样重。",{"type":22,"tag":54,"props":55,"children":57},"h2",{"id":56},"nisotirostide-到底是什么",[58],{"type":27,"value":59},"Nisotirostide 到底是什么",{"type":22,"tag":23,"props":61,"children":62},{},[63,65,70,72,77],{"type":27,"value":64},"Nisotirostide 是一种",{"type":22,"tag":34,"props":66,"children":67},{},[68],{"type":27,"value":69},"激活 Y2 受体的合成肽",{"type":27,"value":71},"（Y2 受体也写作 NPY2R），说白了就是长效的 ",{"type":22,"tag":34,"props":73,"children":74},{},[75],{"type":27,"value":76},"PYY",{"type":27,"value":78}," 类似物，每周皮下注射一次。",{"type":22,"tag":23,"props":80,"children":81},{},[82,84,90,92,101,103,109,111,115],{"type":27,"value":83},"PYY 是人体自己的饱腹信号。小肠下段和结肠里的 L 细胞在进食后把它释放出来——和 GLP-1 一起，出自同一批细胞。进入血液后，释放出来的 PYY",{"type":22,"tag":85,"props":86,"children":87},"sub",{},[88],{"type":27,"value":89},"1-36",{"type":27,"value":91}," 会被剪短成 ",{"type":22,"tag":34,"props":93,"children":94},{},[95,96],{"type":27,"value":76},{"type":22,"tag":85,"props":97,"children":98},{},[99],{"type":27,"value":100},"3-36",{"type":27,"value":102},"，这一剪就换了收件人：长的那一版还会结合 Y1 和 Y5，而这两个受体是",{"type":22,"tag":104,"props":105,"children":106},"em",{},[107],{"type":27,"value":108},"促进",{"type":27,"value":110},"食欲的；PYY",{"type":22,"tag":85,"props":112,"children":113},{},[114],{"type":27,"value":100},{"type":27,"value":116}," 则几乎只找 Y2，而 Y2 是把饥饿感往下压的。所以肥胖研究从来只关心短的那一版。",{"type":22,"tag":23,"props":118,"children":119},{},[120,122,126,128,133],{"type":27,"value":121},"它一直没能变成药，卡在两点上：天然 PYY",{"type":22,"tag":85,"props":123,"children":124},{},[125],{"type":27,"value":100},{"type":27,"value":127}," 的半衰期只有大约 ",{"type":22,"tag":34,"props":129,"children":130},{},[131],{"type":27,"value":132},"10 分钟",{"type":27,"value":134},"，而能让人明显有饱腹感的剂量又会引起恶心。治疗窗窄到这个地步，很难再窄了。整个现代 PYY 类似物家族——包括 Nisotirostide——干的都是同一件事：把这扇窗撑开。把肽改造成能维持几天而不是几分钟，同时让它尽可能只认 Y2，免得顺手激活了那些反而开胃的亲戚。",{"type":22,"tag":23,"props":136,"children":137},{},[138,140,145],{"type":27,"value":139},"有一点要拎清楚：它",{"type":22,"tag":34,"props":141,"children":142},{},[143],{"type":27,"value":144},"不是肠促胰素",{"type":27,"value":146},"。Nisotirostide 不是 GLP-1，不是 GIP，也不是胰高血糖素激动剂，而是一根完全不同的杠杆——这恰恰是它作为搭配对象有意思的地方。两个 GLP-1 叠在一起，无非是把同一个受体打两遍；把 Y2 激动剂放在 GLP-1 旁边，才是真的开了第二条路。",{"type":22,"tag":54,"props":148,"children":150},{"id":149},"大多数文章写到这里就停了",[151],{"type":27,"value":149},{"type":22,"tag":23,"props":153,"children":154},{},[155],{"type":27,"value":156},"真去翻试验登记，会看到一个异常整齐的规律。这就是 LY3457263 全部公开的临床项目：",{"type":22,"tag":158,"props":159,"children":160},"table",{},[161,195],{"type":22,"tag":162,"props":163,"children":164},"thead",{},[165],{"type":22,"tag":166,"props":167,"children":168},"tr",{},[169,175,180,185,190],{"type":22,"tag":170,"props":171,"children":172},"th",{},[173],{"type":27,"value":174},"试验",{"type":22,"tag":170,"props":176,"children":177},{},[178],{"type":27,"value":179},"期别",{"type":22,"tag":170,"props":181,"children":182},{},[183],{"type":27,"value":184},"人群",{"type":22,"tag":170,"props":186,"children":187},{},[188],{"type":27,"value":189},"测的是什么",{"type":22,"tag":170,"props":191,"children":192},{},[193],{"type":27,"value":194},"状态",{"type":22,"tag":196,"props":197,"children":198},"tbody",{},[199,233,265,295],{"type":22,"tag":166,"props":200,"children":201},{},[202,208,213,218,228],{"type":22,"tag":203,"props":204,"children":205},"td",{},[206],{"type":27,"value":207},"NCT04641312",{"type":22,"tag":203,"props":209,"children":210},{},[211],{"type":27,"value":212},"1",{"type":22,"tag":203,"props":214,"children":215},{},[216],{"type":27,"value":217},"健康人 + 2 型糖尿病，n = 67",{"type":22,"tag":203,"props":219,"children":220},{},[221,223],{"type":27,"value":222},"单次给药，单用",{"type":22,"tag":34,"props":224,"children":225},{},[226],{"type":27,"value":227},"以及与度拉糖肽合用",{"type":22,"tag":203,"props":229,"children":230},{},[231],{"type":27,"value":232},"2021\u002F12 完成",{"type":22,"tag":166,"props":234,"children":235},{},[236,241,245,250,260],{"type":22,"tag":203,"props":237,"children":238},{},[239],{"type":27,"value":240},"NCT05377333",{"type":22,"tag":203,"props":242,"children":243},{},[244],{"type":27,"value":212},{"type":22,"tag":203,"props":246,"children":247},{},[248],{"type":27,"value":249},"2 型糖尿病，n = 94",{"type":22,"tag":203,"props":251,"children":252},{},[253,255],{"type":27,"value":254},"多次给药，单用",{"type":22,"tag":34,"props":256,"children":257},{},[258],{"type":27,"value":259},"以及与 GLP‑1 受体激动剂合用",{"type":22,"tag":203,"props":261,"children":262},{},[263],{"type":27,"value":264},"2023\u002F11 完成",{"type":22,"tag":166,"props":266,"children":267},{},[268,273,277,282,290],{"type":22,"tag":203,"props":269,"children":270},{},[271],{"type":27,"value":272},"NCT05582096",{"type":22,"tag":203,"props":274,"children":275},{},[276],{"type":27,"value":212},{"type":22,"tag":203,"props":278,"children":279},{},[280],{"type":27,"value":281},"超重\u002F肥胖，n = 38",{"type":22,"tag":203,"props":283,"children":284},{},[285],{"type":22,"tag":34,"props":286,"children":287},{},[288],{"type":27,"value":289},"仅与替尔泊肽联用",{"type":22,"tag":203,"props":291,"children":292},{},[293],{"type":27,"value":294},"2023\u002F06 完成",{"type":22,"tag":166,"props":296,"children":297},{},[298,303,308,313,321],{"type":22,"tag":203,"props":299,"children":300},{},[301],{"type":27,"value":302},"NCT06897475",{"type":22,"tag":203,"props":304,"children":305},{},[306],{"type":27,"value":307},"2",{"type":22,"tag":203,"props":309,"children":310},{},[311],{"type":27,"value":312},"2 型糖尿病，n = 240",{"type":22,"tag":203,"props":314,"children":315},{},[316],{"type":22,"tag":34,"props":317,"children":318},{},[319],{"type":27,"value":320},"加在司美格鲁肽或替尔泊肽之上",{"type":22,"tag":203,"props":322,"children":323},{},[324],{"type":27,"value":325},"招募中，2027\u002F01 结束",{"type":22,"tag":23,"props":327,"children":328},{},[329,331,338,340],{"type":27,"value":330},"四项试验，每一项里都坐着一个 GLP-1。唯一一项在肥胖人群里做的——NCT05582096——只测了与",{"type":22,"tag":332,"props":333,"children":335},"a",{"href":334},"\u002Fglp1\u002Ftirzepatide",[336],{"type":27,"value":337},"替尔泊肽",{"type":27,"value":339},"的组合，做了十一周，38 个人，主要终点是耐受性而不是体重。",{"type":22,"tag":34,"props":341,"children":342},{},[343],{"type":27,"value":344},"而且到今天都没有公布结果。",{"type":22,"tag":23,"props":346,"children":347},{},[348],{"type":27,"value":349},"第二个发现就在这儿，也是难听的那个。那项肥胖试验 2023 年 6 月结束，之后并没有跟上任何一个减重的二期。2025 年 3 月启动的那个，是糖尿病试验。药物数据库现在已经把 Nisotirostide 的肥胖适应症标为「非活跃」，最高只走到一期。真正在推进的路线是 2 型糖尿病。",{"type":22,"tag":23,"props":351,"children":352},{},[353],{"type":27,"value":354},"也别过度解读：公司搁置项目的理由多得很，礼来在代谢管线的投资者材料里也仍然放着这个分子。但「Nisotirostide 减肥针即将上市」这幅图，跟档案一对就散了。",{"type":22,"tag":54,"props":356,"children":358},{"id":357},"正在做的那项试验究竟在测什么",[359],{"type":27,"value":360},"正在做的那项试验，究竟在测什么",{"type":22,"tag":23,"props":362,"children":363},{},[364,368],{"type":22,"tag":34,"props":365,"children":366},{},[367],{"type":27,"value":302},{"type":27,"value":369}," 是眼下正在跑的研究，值得逐条读，因为它被引用错的次数实在太多。",{"type":22,"tag":23,"props":371,"children":372},{},[373,375,380,382,388,390,395],{"type":27,"value":374},"入组的是",{"type":22,"tag":34,"props":376,"children":377},{},[378],{"type":27,"value":379},"2 型糖尿病",{"type":27,"value":381},"成人，HbA1c 在 7.5% 到 10.5% 之间，BMI 不低于 27，已经稳定使用",{"type":22,"tag":332,"props":383,"children":385},{"href":384},"\u002Fglp1\u002Fsemaglutide",[386],{"type":27,"value":387},"司美格鲁肽",{"type":27,"value":389},"或替尔泊肽至少三个月，",{"type":22,"tag":34,"props":391,"children":392},{},[393],{"type":27,"value":394},"血糖却仍然没达标",{"type":27,"value":396},"。这些人在原有治疗之上，每周再加一针 Nisotirostide 或安慰剂，共三个盲态剂量组。240 人，双盲，研究中心分布在美国、加拿大、德国、波兰、波多黎各和英国。",{"type":22,"tag":23,"props":398,"children":399},{},[400,405,407,412],{"type":22,"tag":34,"props":401,"children":402},{},[403],{"type":27,"value":404},"主要终点是第 24 周的 HbA1c 降幅",{"type":27,"value":406},"，体重变化是",{"type":22,"tag":104,"props":408,"children":409},{},[410],{"type":27,"value":411},"次要",{"type":27,"value":413},"终点。这不是咬文嚼字：试验的样本量是按主要终点算的，入组标准也跟着它走。这里挑的是血糖失控的人，不是想把体重减到最多的人。",{"type":22,"tag":23,"props":415,"children":416},{},[417],{"type":27,"value":418},"至于剂量：三个组的名字就直接叫「Dose 1」「Dose 2」「Dose 3」，具体毫克数没有公开。所以谁要是给你报一个 Nisotirostide 的剂量，那不是从试验里读来的——试验里根本没写。",{"type":22,"tag":23,"props":420,"children":421},{},[422,424,429],{"type":27,"value":423},"最早可能出结果的时间点是 ",{"type":22,"tag":34,"props":425,"children":426},{},[427],{"type":27,"value":428},"2026 年 12 月",{"type":27,"value":430},"的主要完成日，整项研究到 2027 年 1 月收尾。",{"type":22,"tag":54,"props":432,"children":434},{"id":433},"一个-pyy-类似物叠上去实际能换来多少",[435],{"type":27,"value":436},"一个 PYY 类似物叠上去，实际能换来多少",{"type":22,"tag":23,"props":438,"children":439},{},[440],{"type":27,"value":441},"关于 Nisotirostide 本身，没有已发表的疗效数据。但关于这一类药物有——而且有一项记录得异常干净的实验，问的恰好就是我们关心的问题：在已经用着司美格鲁肽的基础上，加一个每周一次的 Y2 类似物，会怎样？",{"type":22,"tag":23,"props":443,"children":444},{},[445,447,452],{"type":27,"value":446},"诺和诺德用它自己的分子 ",{"type":22,"tag":34,"props":448,"children":449},{},[450],{"type":27,"value":451},"PYY1875",{"type":27,"value":453}," 把这件事从大鼠一路做到二期，2025 年整套发表。分子和 Nisotirostide 不同，原理一模一样：选择性 Y2 激动剂，半衰期约 10 天，每周一针。",{"type":22,"tag":23,"props":455,"children":456},{},[457,459,464],{"type":27,"value":458},"**动物实验里效果相当惊人。**肥胖大鼠单用司美格鲁肽掉了 12.5% 的体重，司美格鲁肽加 PYY1875 则掉了 ",{"type":22,"tag":34,"props":460,"children":461},{},[462],{"type":27,"value":463},"24.6%",{"type":27,"value":465},"，进食量从 389 克降到 215 克。顺带一提，PYY1875 单用什么也没干成，那组动物反而还长胖了。效果只存在于组合之中——教科书式的协同。",{"type":22,"tag":23,"props":467,"children":468},{},[469,471,476],{"type":27,"value":470},"**到了人身上，剩下的就没多少了。**二期的设计是严丝合缝对着「叠加」这个问题来的：先开放标签用 32 周司美格鲁肽 2.4 mg 打底，这一段受试者平均减掉 14.3%，从 102.1 公斤降到 87.5 公斤；",{"type":22,"tag":104,"props":472,"children":473},{},[474],{"type":27,"value":475},"然后",{"type":27,"value":477},"才随机分组，在继续用司美格鲁肽的前提下加 PYY1875 或安慰剂。",{"type":22,"tag":23,"props":479,"children":480},{},[481],{"type":27,"value":482},"再走 16 周之后的结果：",{"type":22,"tag":158,"props":484,"children":485},{},[486,500],{"type":22,"tag":162,"props":487,"children":488},{},[489],{"type":22,"tag":166,"props":490,"children":491},{},[492,495],{"type":22,"tag":170,"props":493,"children":494},{},[],{"type":22,"tag":170,"props":496,"children":497},{},[498],{"type":27,"value":499},"第 32 周之后额外减掉的体重",{"type":22,"tag":196,"props":501,"children":502},{},[503,516,529],{"type":22,"tag":166,"props":504,"children":505},{},[506,511],{"type":22,"tag":203,"props":507,"children":508},{},[509],{"type":27,"value":510},"PYY1875 1.0 mg + 司美格鲁肽 2.4 mg",{"type":22,"tag":203,"props":512,"children":513},{},[514],{"type":27,"value":515},"−5.6%",{"type":22,"tag":166,"props":517,"children":518},{},[519,524],{"type":22,"tag":203,"props":520,"children":521},{},[522],{"type":27,"value":523},"安慰剂 + 司美格鲁肽 2.4 mg",{"type":22,"tag":203,"props":525,"children":526},{},[527],{"type":27,"value":528},"−3.1%",{"type":22,"tag":166,"props":530,"children":531},{},[532,540],{"type":22,"tag":203,"props":533,"children":534},{},[535],{"type":22,"tag":34,"props":536,"children":537},{},[538],{"type":27,"value":539},"差值",{"type":22,"tag":203,"props":541,"children":542},{},[543,548,550],{"type":22,"tag":34,"props":544,"children":545},{},[546],{"type":27,"value":547},"−2.2 个百分点",{"type":27,"value":549},"（95% CI −4.2 至 −0.1），约合 ",{"type":22,"tag":34,"props":551,"children":552},{},[553],{"type":27,"value":554},"2.2 公斤",{"type":22,"tag":23,"props":556,"children":557},{},[558],{"type":27,"value":559},"两公斤。统计学上勉强站住，置信区间的下缘几乎贴到零。",{"type":22,"tag":23,"props":561,"children":562},{},[563,565,570,572,577],{"type":27,"value":564},"代价却不小。",{"type":22,"tag":34,"props":566,"children":567},{},[568],{"type":27,"value":569},"联合组有 68% 的人出现胃肠道不良反应",{"type":27,"value":571},"，而司美格鲁肽加安慰剂那组是 29%。重度事件：15% 对 4%。因不良反应停药：21.3% 对 10.7%。47 名受试者里只有 30 人曾经加到目标剂量，到治疗结束时还留在目标剂量上的仅剩 ",{"type":22,"tag":34,"props":573,"children":574},{},[575],{"type":27,"value":576},"20 人，也就是 42.6%",{"type":27,"value":578},"。",{"type":22,"tag":23,"props":580,"children":581},{},[582,584,589],{"type":27,"value":583},"更高的那个剂量组干脆没做完：八个人里有",{"type":22,"tag":34,"props":585,"children":586},{},[587],{"type":27,"value":588},"七个",{"type":27,"value":590},"在第 3 到第 12 周之间因为胃肠道反应退出。作者的结论原文是：作为司美格鲁肽的加药，疗效有限，「但耐受性并不好」。",{"type":22,"tag":23,"props":592,"children":593},{},[594],{"type":27,"value":595},"这不是脚注，而是关于这个思路目前最有信息量的一个数据点。它不代表 Nisotirostide 注定失败——分子不同、选择性不同、爬坡方案不同，而且礼来用替尔泊肽证明过自己是把耐受性当回事的。但它把举证责任挪了个位置。谁要说 PYY 类似物是你 GLP-1 方案的大幅增效器，就得解释清楚这次凭什么不一样。",{"type":22,"tag":54,"props":597,"children":599},{"id":598},"竞争对手以及这场比赛为什么已经换了场地",[600],{"type":27,"value":601},"竞争对手——以及这场比赛为什么已经换了场地",{"type":22,"tag":23,"props":603,"children":604},{},[605,607,612],{"type":27,"value":606},"就在 PYY 上着这一课的同时，另一类药物把「GLP-1 上面该加什么」回答得相当有说服力：",{"type":22,"tag":34,"props":608,"children":609},{},[610],{"type":27,"value":611},"胰淀素",{"type":27,"value":578},{"type":22,"tag":23,"props":614,"children":615},{},[616,621,623,628,630,635,637,642],{"type":22,"tag":34,"props":617,"children":618},{},[619],{"type":27,"value":620},"CagriSema",{"type":27,"value":622},"（卡格列奈肽 + 司美格鲁肽，诺和诺德）是已经做完的那份答卷。三期试验 REDEFINE 1 纳入 3417 名无 2 型糖尿病的成人，第 68 周平均减重 ",{"type":22,"tag":34,"props":624,"children":625},{},[626],{"type":27,"value":627},"20.4%",{"type":27,"value":629},"；在完整坚持治疗的人群中是 ",{"type":22,"tag":34,"props":631,"children":632},{},[633],{"type":27,"value":634},"22.7%",{"type":27,"value":636},"，其中 40.4% 减掉了至少四分之一的体重。同一项试验里作对照：卡格列奈肽单用 11.5%，司美格鲁肽单用 14.9%，安慰剂 3%。在",{"type":22,"tag":34,"props":638,"children":639},{},[640],{"type":27,"value":641},"合并",{"type":27,"value":643},"2 型糖尿病人群的 REDEFINE 2 中，是 13.7% 对安慰剂 3.4%，并有 74% 的人把 HbA1c 降到 6.5% 及以下。",{"type":22,"tag":23,"props":645,"children":646},{},[647,652],{"type":22,"tag":34,"props":648,"children":649},{},[650],{"type":27,"value":651},"Eloralintide",{"type":27,"value":653},"（LY3841136）是礼来自家的胰淀素——它的数字也解释了公司内部的注意力在往哪儿挪。2025 年 11 月公布的 48 周二期，263 名无糖尿病成人：",{"type":22,"tag":158,"props":655,"children":656},{},[657,673],{"type":22,"tag":162,"props":658,"children":659},{},[660],{"type":22,"tag":166,"props":661,"children":662},{},[663,668],{"type":22,"tag":170,"props":664,"children":665},{},[666],{"type":27,"value":667},"Eloralintide，每周一次",{"type":22,"tag":170,"props":669,"children":670},{},[671],{"type":27,"value":672},"48 周减重",{"type":22,"tag":196,"props":674,"children":675},{},[676,689,702,715,728,741],{"type":22,"tag":166,"props":677,"children":678},{},[679,684],{"type":22,"tag":203,"props":680,"children":681},{},[682],{"type":27,"value":683},"1 mg",{"type":22,"tag":203,"props":685,"children":686},{},[687],{"type":27,"value":688},"−9.5%",{"type":22,"tag":166,"props":690,"children":691},{},[692,697],{"type":22,"tag":203,"props":693,"children":694},{},[695],{"type":27,"value":696},"3 mg",{"type":22,"tag":203,"props":698,"children":699},{},[700],{"type":27,"value":701},"−12.4%",{"type":22,"tag":166,"props":703,"children":704},{},[705,710],{"type":22,"tag":203,"props":706,"children":707},{},[708],{"type":27,"value":709},"6 mg",{"type":22,"tag":203,"props":711,"children":712},{},[713],{"type":27,"value":714},"−17.6%",{"type":22,"tag":166,"props":716,"children":717},{},[718,723],{"type":22,"tag":203,"props":719,"children":720},{},[721],{"type":27,"value":722},"9 mg",{"type":22,"tag":203,"props":724,"children":725},{},[726],{"type":27,"value":727},"−20.1%",{"type":22,"tag":166,"props":729,"children":730},{},[731,736],{"type":22,"tag":203,"props":732,"children":733},{},[734],{"type":27,"value":735},"6\u002F9 mg 爬坡",{"type":22,"tag":203,"props":737,"children":738},{},[739],{"type":27,"value":740},"−19.9%",{"type":22,"tag":166,"props":742,"children":743},{},[744,749],{"type":22,"tag":203,"props":745,"children":746},{},[747],{"type":27,"value":748},"安慰剂",{"type":22,"tag":203,"props":750,"children":751},{},[752],{"type":27,"value":753},"−0.4%",{"type":22,"tag":23,"props":755,"children":756},{},[757,759,764],{"type":27,"value":758},"二十个百分点——而且是",{"type":22,"tag":34,"props":760,"children":761},{},[762],{"type":27,"value":763},"单药",{"type":27,"value":765},"，旁边没有任何肠促胰素。真正值得注意的是耐受性：以轻到中度的胃肠道症状和乏力为主，1 mg 和 3 mg 组与安慰剂相当，爬坡放慢之后还明显更少。礼来已经宣布启动单药三期，同时在并行测试与替尔泊肽的组合。",{"type":22,"tag":23,"props":767,"children":768},{},[769],{"type":27,"value":770},"把这两张图并排放着看。Y2 激动剂加在司美格鲁肽上，买到大约两个百分点，代价是三分之二的人不舒服；胰淀素激动剂自己就买到二十个百分点，而且耐受良好。钱会往哪边流，没什么悬念。",{"type":22,"tag":23,"props":772,"children":773},{},[774],{"type":27,"value":775},"其余的赛道，一并列全：",{"type":22,"tag":158,"props":777,"children":778},{},[779,804],{"type":22,"tag":162,"props":780,"children":781},{},[782],{"type":22,"tag":166,"props":783,"children":784},{},[785,790,795,800],{"type":22,"tag":170,"props":786,"children":787},{},[788],{"type":27,"value":789},"药物",{"type":22,"tag":170,"props":791,"children":792},{},[793],{"type":27,"value":794},"是什么",{"type":22,"tag":170,"props":796,"children":797},{},[798],{"type":27,"value":799},"自家试验的最好成绩",{"type":22,"tag":170,"props":801,"children":802},{},[803],{"type":27,"value":194},{"type":22,"tag":196,"props":805,"children":806},{},[807,832,857,883,909,935,965],{"type":22,"tag":166,"props":808,"children":809},{},[810,817,822,827],{"type":22,"tag":203,"props":811,"children":812},{},[813],{"type":22,"tag":34,"props":814,"children":815},{},[816],{"type":27,"value":620},{"type":22,"tag":203,"props":818,"children":819},{},[820],{"type":27,"value":821},"胰淀素 + GLP‑1（诺和诺德）",{"type":22,"tag":203,"props":823,"children":824},{},[825],{"type":27,"value":826},"68 周 22.7%",{"type":22,"tag":203,"props":828,"children":829},{},[830],{"type":27,"value":831},"三期已完成",{"type":22,"tag":166,"props":833,"children":834},{},[835,842,847,852],{"type":22,"tag":203,"props":836,"children":837},{},[838],{"type":22,"tag":34,"props":839,"children":840},{},[841],{"type":27,"value":651},{"type":22,"tag":203,"props":843,"children":844},{},[845],{"type":27,"value":846},"选择性胰淀素（礼来）",{"type":22,"tag":203,"props":848,"children":849},{},[850],{"type":27,"value":851},"48 周 20.1%，单药",{"type":22,"tag":203,"props":853,"children":854},{},[855],{"type":27,"value":856},"三期启动中",{"type":22,"tag":166,"props":858,"children":859},{},[860,868,873,878],{"type":22,"tag":203,"props":861,"children":862},{},[863],{"type":22,"tag":34,"props":864,"children":865},{},[866],{"type":27,"value":867},"Petrelintide",{"type":22,"tag":203,"props":869,"children":870},{},[871],{"type":27,"value":872},"胰淀素（Zealand\u002F罗氏）",{"type":22,"tag":203,"props":874,"children":875},{},[876],{"type":27,"value":877},"42 周 10.7%",{"type":22,"tag":203,"props":879,"children":880},{},[881],{"type":27,"value":882},"二期阳性（2026\u002F03）",{"type":22,"tag":166,"props":884,"children":885},{},[886,894,899,904],{"type":22,"tag":203,"props":887,"children":888},{},[889],{"type":22,"tag":34,"props":890,"children":891},{},[892],{"type":27,"value":893},"Amycretin",{"type":22,"tag":203,"props":895,"children":896},{},[897],{"type":27,"value":898},"GLP‑1 + 胰淀素合一（诺和诺德）",{"type":22,"tag":203,"props":900,"children":901},{},[902],{"type":27,"value":903},"36 周 24.3%",{"type":22,"tag":203,"props":905,"children":906},{},[907],{"type":27,"value":908},"1b\u002F2a 期",{"type":22,"tag":166,"props":910,"children":911},{},[912,920,925,930],{"type":22,"tag":203,"props":913,"children":914},{},[915],{"type":22,"tag":34,"props":916,"children":917},{},[918],{"type":27,"value":919},"MariTide",{"type":22,"tag":203,"props":921,"children":922},{},[923],{"type":27,"value":924},"GLP‑1 激动 + GIP 阻断，每月一次（安进）",{"type":22,"tag":203,"props":926,"children":927},{},[928],{"type":27,"value":929},"52 周约 20%",{"type":22,"tag":203,"props":931,"children":932},{},[933],{"type":27,"value":934},"二期",{"type":22,"tag":166,"props":936,"children":937},{},[938,950,955,960],{"type":22,"tag":203,"props":939,"children":940},{},[941],{"type":22,"tag":34,"props":942,"children":943},{},[944],{"type":22,"tag":332,"props":945,"children":947},{"href":946},"\u002Fglp1\u002Fretatrutide",[948],{"type":27,"value":949},"Retatrutide",{"type":22,"tag":203,"props":951,"children":952},{},[953],{"type":27,"value":954},"GLP‑1 + GIP + 胰高血糖素（礼来）",{"type":22,"tag":203,"props":956,"children":957},{},[958],{"type":27,"value":959},"48 周约 24%",{"type":22,"tag":203,"props":961,"children":962},{},[963],{"type":27,"value":964},"三期",{"type":22,"tag":166,"props":966,"children":967},{},[968,975,983,991],{"type":22,"tag":203,"props":969,"children":970},{},[971],{"type":22,"tag":34,"props":972,"children":973},{},[974],{"type":27,"value":38},{"type":22,"tag":203,"props":976,"children":977},{},[978],{"type":22,"tag":34,"props":979,"children":980},{},[981],{"type":27,"value":982},"Y2\u002FPYY 激动剂（礼来）",{"type":22,"tag":203,"props":984,"children":985},{},[986],{"type":22,"tag":34,"props":987,"children":988},{},[989],{"type":27,"value":990},"无公开数据",{"type":22,"tag":203,"props":992,"children":993},{},[994],{"type":22,"tag":34,"props":995,"children":996},{},[997],{"type":27,"value":998},"二期，糖尿病",{"type":22,"tag":23,"props":1000,"children":1001},{},[1002],{"type":27,"value":1003},"最后那一行，就是整篇文章浓缩成的一行。",{"type":22,"tag":54,"props":1005,"children":1007},{"id":1006},"回到最初那个问题老实回答",[1008],{"type":27,"value":1009},"回到最初那个问题，老实回答",{"type":22,"tag":23,"props":1011,"children":1012},{},[1013],{"type":27,"value":1014},"能不能把 Nisotirostide 当成一款和替尔泊肽或司美格鲁肽叠着用的减肥针？",{"type":22,"tag":23,"props":1016,"children":1017},{},[1018],{"type":27,"value":1019},"**从概念上：能，而且它本来就是这么设计的。**它不是肠促胰素，走的是另一条饱腹通路，所有试验把它和 GLP-1 配在一起正是出于这个理由。药理逻辑是站得住的。",{"type":22,"tag":23,"props":1021,"children":1022},{},[1023],{"type":27,"value":1024},"**从证据上：不能，至少今天不能。**关于这个分子的已发表疗效数字是零。唯一一项肥胖试验是 38 人、十一周的耐受性研究，而且没有公布结果。在推进的开发路线冲的是血糖不是体重。而这一类药物唯一完整发表的人体实验，换来大约两公斤，代价是把五分之一的受试者赶出了研究。",{"type":22,"tag":23,"props":1026,"children":1027},{},[1028,1030,1036,1038,1044],{"type":27,"value":1029},"再加上那条永远不变的：眼下以「Nisotirostide」名义流通的东西，按定义就是未获批准、身份和纯度都不明的灰市货。一个 NCT 编号不为陌生人寄给你的那支西林瓶背书——在这件事上它甚至连剂量都背书不了，因为试验剂量是盲的。完整的法律图景见我们的基础文章",{"type":22,"tag":332,"props":1031,"children":1033},{"href":1032},"\u002Fare-peptides-legal",[1034],{"type":27,"value":1035},"肽类合法吗？",{"type":27,"value":1037},"；想从头看起，就是",{"type":22,"tag":332,"props":1039,"children":1041},{"href":1040},"\u002Fwhat-are-peptides",[1042],{"type":27,"value":1043},"什么是肽",{"type":27,"value":578},{"type":22,"tag":54,"props":1046,"children":1048},{"id":1047},"值得盯住的时间点",[1049],{"type":27,"value":1047},{"type":22,"tag":23,"props":1051,"children":1052},{},[1053,1055,1060],{"type":27,"value":1054},"这个故事还有没有下文，只由一个日期决定：",{"type":22,"tag":34,"props":1056,"children":1057},{},[1058],{"type":27,"value":1059},"NCT06897475 在 2026 年 12 月的主要完成",{"type":27,"value":1061},"。到那时才第一次会有关于这个分子本身的数字——HbA1c 为主、体重为辅，对照安慰剂，叠在司美格鲁肽或替尔泊肽之上。如果体重曲线明显往下走、脱落率又还过得去，那条被搁置的肥胖路线会很快回来；如果曲线是平的，或者胃肠道那一幕重演，这个问题也就到此为止。",{"type":22,"tag":23,"props":1063,"children":1064},{},[1065],{"type":27,"value":1066},"在那之前，Nisotirostide 是一个用来观察的分子，不是用来搞到手的。",{"type":22,"tag":54,"props":1068,"children":1070},{"id":1069},"这对今天的你意味着什么",[1071],{"type":27,"value":1069},{"type":22,"tag":23,"props":1073,"children":1074},{},[1075,1077,1083,1085,1091,1093,1099],{"type":27,"value":1076},"对于人们实际在用的那些药，中立的部分是算账。要记录自己手上有什么、浓度多少、什么时候用的，",{"type":22,"tag":332,"props":1078,"children":1080},{"href":1079},"\u002Fpeptides-list",[1081],{"type":27,"value":1082},"我们的肽类追踪器",{"type":27,"value":1084},"就是为这件事做的。如果复溶是那个让你心里没底的步骤，",{"type":22,"tag":332,"props":1086,"children":1088},{"href":1087},"\u002Fcalculator",[1089],{"type":27,"value":1090},"我们的计算器",{"type":27,"value":1092},"能在你知道西林瓶浓度和加进去的抑菌注射用水之后，把目标剂量换算成注射器上的刻度。而既然是每周一针、血药水平在两针之间起起落落，",{"type":22,"tag":332,"props":1094,"children":1096},{"href":1095},"\u002Fplotter",[1097],{"type":27,"value":1098},"血药水平曲线图",{"type":27,"value":1100},"会把这条曲线画出来。这些都不是在建议你去用什么——只是把账算清楚而已。",{"type":22,"tag":54,"props":1102,"children":1104},{"id":1103},"结论",[1105],{"type":27,"value":1103},{"type":22,"tag":23,"props":1107,"children":1108},{},[1109],{"type":27,"value":1110},"Nisotirostide（LY3457263）是礼来那款作用于 Y2 受体、每周一次的 PYY 类似物，它确实是按搭配用药设计的，也从来没被别的方式试过——论坛叙事里这一半是真的。另一半不成立：没有公开的疗效数据，唯一的肥胖试验只是一项没有结果的小型耐受性研究，在推进的开发路线是 2 型糖尿病，而这一类药物最好的已发表实验换来大约两公斤外加 68% 的胃肠道不良反应。与此同时，胰淀素已经把组合这道题答完了：CagriSema 的 22.7%，以及 eloralintide 单枪匹马的 20.1% 且耐受良好。想看下一代减重药往哪儿走，就看胰淀素。Nisotirostide 是一条有意思的脚注，附带一个 2026 年 12 月的日期——还算不上答案。",{"type":22,"tag":54,"props":1112,"children":1114},{"id":1113},"参考来源",[1115],{"type":27,"value":1113},{"type":22,"tag":1117,"props":1118,"children":1119},"ul",{},[1120,1134,1145,1156,1167,1179,1191,1203,1215,1227,1239],{"type":22,"tag":1121,"props":1122,"children":1123},"li",{},[1124,1126],{"type":27,"value":1125},"ClinicalTrials.gov，",{"type":22,"tag":332,"props":1127,"children":1131},{"href":1128,"rel":1129},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06897475",[1130],"nofollow",[1132],{"type":27,"value":1133},"NCT06897475 — LY3457263 加在司美格鲁肽或替尔泊肽之上治疗 2 型糖尿病（二期）",{"type":22,"tag":1121,"props":1135,"children":1136},{},[1137,1138],{"type":27,"value":1125},{"type":22,"tag":332,"props":1139,"children":1142},{"href":1140,"rel":1141},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05582096",[1130],[1143],{"type":27,"value":1144},"NCT05582096 — LY3457263 与替尔泊肽联用于超重\u002F肥胖（一期）",{"type":22,"tag":1121,"props":1146,"children":1147},{},[1148,1149],{"type":27,"value":1125},{"type":22,"tag":332,"props":1150,"children":1153},{"href":1151,"rel":1152},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05377333",[1130],[1154],{"type":27,"value":1155},"NCT05377333 — LY3457263 单用及与 GLP-1 受体激动剂合用于 2 型糖尿病（一期）",{"type":22,"tag":1121,"props":1157,"children":1158},{},[1159,1160],{"type":27,"value":1125},{"type":22,"tag":332,"props":1161,"children":1164},{"href":1162,"rel":1163},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04641312",[1130],[1165],{"type":27,"value":1166},"NCT04641312 — 首次人体单次递增剂量研究（一期）",{"type":22,"tag":1121,"props":1168,"children":1169},{},[1170,1172],{"type":27,"value":1171},"Wulff 等，Obesity 2025，",{"type":22,"tag":332,"props":1173,"children":1176},{"href":1174,"rel":1175},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Foby.24329",[1130],[1177],{"type":27,"value":1178},"Long-acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies",{"type":22,"tag":1121,"props":1180,"children":1181},{},[1182,1184],{"type":27,"value":1183},"Østergaard 等，Science Translational Medicine 2025，",{"type":22,"tag":332,"props":1185,"children":1188},{"href":1186,"rel":1187},"https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fscitranslmed.adq6392",[1130],[1189],{"type":27,"value":1190},"Variant screening of PYY3–36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity",{"type":22,"tag":1121,"props":1192,"children":1193},{},[1194,1196],{"type":27,"value":1195},"礼来，",{"type":22,"tag":332,"props":1197,"children":1200},{"href":1198,"rel":1199},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated-meaningful-weight-loss-and-favorable-tolerability-in-a-phase-2-study-of-adults-with-obesity-or-overweight-302607061.html",[1130],[1201],{"type":27,"value":1202},"Eloralintide：选择性胰淀素激动剂的二期结果",{"type":22,"tag":1121,"props":1204,"children":1205},{},[1206,1208],{"type":27,"value":1207},"诺和诺德 \u002F NEJM，",{"type":22,"tag":332,"props":1209,"children":1212},{"href":1210,"rel":1211},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fcagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html",[1130],[1213],{"type":27,"value":1214},"CagriSema 2.4 mg\u002F2.4 mg 在 REDEFINE 1 中平均减重 22.7%",{"type":22,"tag":1121,"props":1216,"children":1217},{},[1218,1220],{"type":27,"value":1219},"NEJM 2025，",{"type":22,"tag":332,"props":1221,"children":1224},{"href":1222,"rel":1223},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fabs\u002F10.1056\u002FNEJMoa2502082",[1130],[1225],{"type":27,"value":1226},"Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes（REDEFINE 2）",{"type":22,"tag":1121,"props":1228,"children":1229},{},[1230,1232],{"type":27,"value":1231},"罗氏，",{"type":22,"tag":332,"props":1233,"children":1236},{"href":1234,"rel":1235},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-03-05",[1130],[1237],{"type":27,"value":1238},"胰淀素类似物 petrelintide 的二期阳性结果",{"type":22,"tag":1121,"props":1240,"children":1241},{},[1242,1244],{"type":27,"value":1243},"安进，",{"type":22,"tag":332,"props":1245,"children":1248},{"href":1246,"rel":1247},"https:\u002F\u002Fwww.amgen.com\u002Fnewsroom\u002Fpress-releases\u002F2024\u002F11\u002Famgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52-weeks-in-a-phase-2-study",[1130],[1249],{"type":27,"value":1250},"MariTide 二期 52 周结果",{"title":7,"searchDepth":1252,"depth":1252,"links":1253},2,[1254,1255,1256,1257,1258,1259,1260,1261,1262,1263],{"id":56,"depth":1252,"text":59},{"id":149,"depth":1252,"text":149},{"id":357,"depth":1252,"text":360},{"id":433,"depth":1252,"text":436},{"id":598,"depth":1252,"text":601},{"id":1006,"depth":1252,"text":1009},{"id":1047,"depth":1252,"text":1047},{"id":1069,"depth":1252,"text":1069},{"id":1103,"depth":1252,"text":1103},{"id":1113,"depth":1252,"text":1113},"markdown","content:blog:zh:nisotirostide-ly3457263.md","content","blog\u002Fzh\u002Fnisotirostide-ly3457263.md","blog\u002Fzh\u002Fnisotirostide-ly3457263","md"]